WHO Updates Flu Vaccine Strains as Sino Biological Launches Antigens for 2026-2027 Season

The World Health Organization has announced critical updates to the 2026-2027 Northern Hemisphere influenza vaccine composition, responding to two significant viral developments that threaten global health. The WHO's recommendations highlight the continued spread of the A (H3N2) subclade K strain, which has become dominant worldwide since August 2025 due to its enhanced immune escape capabilities, and the growing circulation of new B/Victoria lineage strains, whose activity has surged from 6% to over 20% in regions like Hong Kong and the United States. These trends have prompted the selection of new reference viruses: A/Darwin/1454/2025 for H3N2 (both egg-based and cell-based), A/Missouri/11/2025 for H1N1 (egg-based and cell-based), and B/Tokyo/EIS13-175/2025 (egg-based) and B/Pennsylvania/14/2025 (cell-based) for influenza B strains.

In rapid response to these WHO recommendations, Sino Biological, Inc., a global biotechnology leader specializing in recombinant technology, has launched a comprehensive panel of antigens specifically designed for the 2026-2027 Northern Hemisphere influenza vaccine strains to accelerate vaccine development worldwide. The company's extensive portfolio includes recombinant antigens for key viral components such as Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP), with immediate availability of H1N1 reagents for A/Missouri/11/2025 and H3N2 subclade K proteins aligned with A/Darwin/1454/2025. Additionally, Sino Biological is developing influenza B reagents for the newly recommended strains and offers stable HA trimers that maintain native conformation for accurate immune characterization, all validated through advanced methods like SEC-MALS to ensure high purity and activity.

Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company's commitment to providing the scientific community with high-quality tools swiftly during infectious disease threats, stating that their mission is to advance global influenza preparedness and vaccine innovation. As a company serving researchers in over 90 countries, Sino Biological's initiative supports critical areas from basic research to drug discovery and diagnostics, reinforcing its role in the global health ecosystem. For more details, view the original release on www.newmediawire.com, which covers the full scope of this development and Sino Biological's contributions to combating seasonal influenza through cutting-edge biotechnology solutions.